Tech Transfer Tidbits

Premium

Stanford Spinout Eiger Biopharma Licenses Hep C Drug Targets from School

Eiger Biopharmaceuticals, a recent spinout of Stanford University, said last week that it has licensed the exclusive rights to a hepatitis C virus technology from the university.

The technology, discovered in the laboratory of Stanford researcher and Eiger co-founder Jeffrey Glenn, pertains to a variety of drug targets, including key features of NS4B, a non-structural protein in the HCV genome that binds to HCV-RNA and is required for viral replication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.